To present a managerial approach for evaluating the performance of a drug prior authorization (PA) program, illustrated through an evaluation of the Iowa Medicaid drug PA program.
PRIOR AUTHORIZATION
The purpose of drug prior authorization is to affect prescribing patterns. More specifically, it is designed to limit or restrict selected high-cost prescribing decisions. For instance, PA guidelines may: 1) encourage the use of generics; 2) encourage the use of alternative, less costly drugs which can be used for the same Prior authorization and similar programs should operate in a way that does not unduly hinder patient care. A program that achieves its goal of altering prescribing, but does so at the expense of provider and patient satisfaction, may not be beneficial in the longer term in a competitive marketplace that emphasizes customer satisfaction. The way these programs operate is tied directly to patient and prescriber satisfaction. long processing times for PA requests may delay the start of therapy and diminish quality of care. High denial rates may indicate poor guideline interpretation or provider communication, both of which are program administration problems. Thus, measurement of PA program performance along such dimensions as response times, approval rates, and access is important in assessing the degree to which the program is as efficient as it is effective.
THE IOWA MEDICAID DRUG PA PROGRAM
The Iowa Medicaid drug program, which covers roughly 250,000 recipients and more than four million prescriptions,S initiated PA in October 1992 and expanded it in August 1993. All guidelines for the PA program were developed by the Iowa Medicaid Drug Use Review Commission, a committee of prescribers and pharmacists that conducts the state's retrospective drug use review program and related activities. During the study, the program included prior authorization for 16 categories of individual medications, each with specific criteria.
These broad categories included: amphetamine or ampheta-mine-like sympathomimetics for certain diagnoses; some legend andnonlegend multivitamins, tonic preparations, and associated combinations for specific conditions; c10zapine under strict criteria; single-source NSAIDs; single-source benzodiazepine sedative hypnotics; H2-receptor antagonists and sucralfate at full therapeutic doses; omeprazole; misoprostol; growth hormones; prescription anti acne products; topical tretinoin; nonsedating antihistamines; dipyridamole; cephalexin hydrochloride monohydrate; epoetin; and filgrastim.
The 
PROGRAM OPERATIONS METHODS
One concern of any initiative such as PA is that it operate efficiently as well as produce savings and better outcomes. To measure efficiency, the Iowa PA program was evaluated on workload, response time, and approval rates. Program operations data were recorded by PA personnel for every inquiry during a two-week period (August 16-August 29, 1995). Inquiries dealing with coverage decisions and medication requests were logged daily by PA personnel in a computer database (see Table 1 ). For this study, they also logged the time of day a new request was resolved. Extension requests (requests for patients to continue a PA medication) and all other 2,3 were assigned monetary values, using prices paid by Medicaid during the study period (FY 1995) . Prices were adjusted to reflect estimated rebates from drug manufacturers. Overall, the Iowa Medicaid program received rebates amounting to about 20% of drug payments in 1995.' Since the rebates differ for branded and generic products, the assumption was made that brand name products were associated with a 20% rebate and generic products were associated with no rebate. It also was assumed that nonsedating antihistamine and antiulcer products were branded and, hence, associated with rebates, while sedating antihistamines were assumed to be generic. Results were recalculated using a 30% rebate for branded products and none for generics. This step addressed the question: What is the amount saved (or spent) in drug expenditures because PA has altered prescribing patterns?
The category was multiplied by the total cost to give the cost for that category (see Table 5 ).
OPERATIONAL RESULTS
During the two-week data collection period, 1,402 contacts were tracked. Of these, 92.6% were telephone contacts. An addi-tionaI6.2% were received by fax, and the remaining 1.2% of contacts arrived by mail. These contacts included new PA requests, requests for PA extensions, and related calls ranging from general program questions to providers submitting additional patient in-fOllnation. The sample data appeared to be representative of the 
Response Time
Because of differences in procedures for extending an existing FA and researching a new PA request, the response times were calculated separately Also, response times by drug classification and by outcome (approval vs. denial) also were reviewed. 
RESULTS

Drug Use and Expenditures
A summary of the potential effects of PA on drug use and drug expenditures for the four categories is shown in Table 5 .
The changes in behavior or drug use between the baseline period and study period were quite pronounced. In 1995, generic prescriptions represented 87% and 89% of all antiarthritic and benzodiazepine prescriptions; during the baseline period, this figure ranged from 49% to 54% every month for both cate- figure was about 57% during the study period. Finally, the use of sedating antihistamines, ranging from 48% to 60% of all antihistamine prescriptions during the baseline months, was 91 % in the study period. Given the differences in prices between the alternatives (i.e., a generic prescription compared to brand), the potential gross savings were: a) antiarthritics: $1,493,000; b) benzodiazepines: $1,475,000; c) antiulcer: $738,000; and d) antihistamines: $290,000. As mentioned earlier, other factors beside PA may have affected prescribing patterns between the baseline and study periods; to account for this, an assumption was made that two-thirds of the change was due to PA and the remainder to other factors. Thus, the gross savings for all categories studied were estimated to range from $2,676,000 to $3,996,000. Also included in Table 5 is the estimated administrative cost associated with each category, totaling $162,000.
Thus, total net savings (gross savings less administrative costs)
for the four categories was $2.51 million to $3.83 million. By category, the net savings ranges were: a) antiarthritics: $970,000 to $1,463,000; b) benzodiazepines: $982,000 to $1,469,000; c) antiulcer: $388,000 to $632,000; and d) antihistamines: $174,000 to $270,000. appear to be positive, they suffer from the lack of comparisons with other programs. Expected levels of performance in PA programs (turnaround times, approval rates, administrative costs) are not known, hence the difficulty in judging performance. With respect to the financial consequences, the analysis focused on four prescribing behaviors encouraged by PA: prescribing genetic antiarthritic and benzodiazepines before using branded products; prescribing sedating rather than nonsedating drugs and using antiulcer therapy in low or maintenance doses after a suitable time on high-dose therapy Prior authorization, in these four categories, was associated with a net reduction in drug expenditures of $2.51 million to $3.83 million. This takes into account both the costs to run the program and rebates from drug manufacturers. To put this in perspective, this represented about 2 % to 3% of drug vendor payments.s Based on this analysis and other published works, prior authorization appears to have a marked effect on prescribing patterns. In the Iowa program, for instance, two years after implementation of PA, the proportions of generic antiarthritic and benzodiazepine use were much higher than before PA (33% and 38%, respectively); yet PA approval rates were 63% and 78%, respectively Prior authorization guidehnes may have been responsible for changing prescribing behaviors, so that potentially deniable prescribing decisions were altered before fonnal requests were made. Whether such changes in behavior would be retained in the absence of the PA program is open to speculation, but given the half-life of other programs, the likelihood is that the effects of the PA program would diminish over time.
Limitations
In conclusion, this article has presented a means of assessing the operational perfonnance of a drug prior authorization program as well as a method of assessing its potential effect on prescribing and drug expenditures. The assessment, from the viewpoint of the third-party payor, uses program-wide data that are commonly avai1able from drug plan administrators. By tracking a minimal number of variables during the daily operations of a prior authorization program, managers can easily assess both the financial savings and the efficiency of their programs. As these programs continue to come under fire by various parties within the health care system, quick and reliable measures of program quality will prove beneficial in supporting the use of these programs.
